Skip to main content

Table 1 Basic information of the research subjects

From: Correlation between circulating advanced glycation end products and thioredoxin-interacting protein levels and renal fat content in type 2 diabetes mellitus patients

Variables

 

Male sex (%)

83 (70.34%)

Age (years)

54.00 (43.75,63.00)

Duartion (month)

66.00 (2.00,120.00)

BMI (kg/ m²)

24.90 (22.66,27.71)

WC (cm)

92.97 ± 12.10

HC (cm)

99.09 ± 9.21

HbA1c (%)

10.50 ± 2.58

FBG (mmol/L)

7.60 (6.15,10.24)

INS (mIU/L)

12.25 (8.23,19.93)

CP (ng/ml)

0.97 (0.62,1.82)

HOMA-IR

4.10 (2.59,8.23)

Cystatin C (mg/L)

0.89 (0.80,0.98)

Scr (mmol/L)

57.15 (49.45,66.48)

eGFR (ml/min/1.73m²)

107.32 ± 19.78

UACR (mg/g)

64.50 (34.00,120.75)

TC (mmol/L)

4.91 ± 1.05

TG (mmol/L)

1.49 (1.01,2.04)

LDL-c (mmol/L)

3.01 ± 0.88

HDL-c (mmol/L)

0.94 (0.80,1.09)

RFF (%)

4.89 (4.61,5.67)

AGEs (ug/ml)

8.51 ± 3.41

sRAGE (ng/ml)

1.70 ± 0.41

TXNIP (pg/ml)

17.94 ± 3.49

DKD (%)

46 (39.00%)

Patients treated with OAD (%)

92 (77.97%)

Patients treated with insulin (%)

26 (22.03%)

  1. Note: (1) The measurement data conforming to normal distribution in the table are expressed as mean ± standard deviation, and the measurement data not conforming to normal distribution are expressed as median (lower Quartile - upper Quartile); Count data is expressed in frequency (Percentile). (2) BMI: Body mass index; WC: Waist circumference; HC: Hip circumference; HbA1c: Glycated hemoglobin; FBG: Fasting blood glucose; CP: C-peptide; INS: Fasting insulin; HOMA-IR: Insulin resistance index; Scr: serum creatinine; eGFR: Glomerular filtration rate; UACR: urinary protein/creatinine; TG: Triglycerides; TC: Total cholesterol; LDL-c: Low-density lipoprotein cholesterol; HDL-c: High-density lipoprotein cholesterol; RFF: renal fat fraction; AGEs: advanced glycation end products; sRAGE: soluble receptor for advanced glycation end products; TXNIP: thioredoxin interacting protein; DKD: diabetic kidney disease; OAD: oral antidiabetic drug